Theralase(R) Demonstrates Effectiveness of X-Ray-Activated Drug

Executive Summary

• Theralase® Technologies announced pre‑clinical data showing that X‑ray‑activated Rutherrin® dramatically enhances tumor cell kill (≈100‑fold vs. radiation alone) across multiple cancer models.
• The study demonstrated synergistic effects including increased ROS production, immune activation, overcoming drug/radiation resistance, and durable immune memory leading to complete tumor regression in colorectal models.
• Company plans to complete GLP toxicology studies in 2026 to advance Rutherrin® into clinical development for GBM, NSCLC, pancreatic, lymphoma and colorectal cancers.

Key Details

• Study Scope: Preclinical evaluation of Rutherrin® (ruthenium‑based small molecule with recombinant human transferrin) activated by radiation therapy in glioblastoma multiforme, lung cancer, colorectal cancer, and lymphoma models.
• Efficacy Findings:
• ~100× increase in cancer cell kill versus radiation alone.

• 10‑fold preferential tumor uptake over healthy brain tissue in GBM models.

• Significant survival extension in both GBM and lung cancer models.
• Complete tumor regression observed in colorectal cancer models, with long‑term protection against rechallenge (durable immune memory).
• Mechanistic Insights:
• Elevated reactive oxygen species (ROS) generation.
• Up‑regulation of immune‑related cytokines and chemokines, driving both immediate cytotoxicity and systemic immunity.
• Modulation of drug efflux pathways, helping to overcome multidrug and radiation resistance.
• Future Development Plan:
• GLP toxicology studies slated for completion in 2026.
• Intended launch of clinical development programs targeting GBM, NSCLC, pancreatic cancer, lymphoma, and colorectal cancer.
• Publications & Access:
• Abstract published in International Journal of Radiation Oncology – Biology – Physics (link provided).
• Full scientific poster available online via Theralase® website and Newsfile image link.

Notable Quotes

“The preclinical research has demonstrated the utility of X‑ray‑activated Rutherrin® as a preferred addition to radiation therapy to increase efficacy, improve local tumor control, overcome treatment resistance and stimulate systemic immunity.” – Mark Roufaiel, Ph.D., Research Scientist

“Next steps in our research program are to complete Good Laboratory Practice toxicology studies in 2026, paving the way for the launch of clinical development targeting GBM, NSCLC, pancreatic, lymphoma and colorectal cancers.” – Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer

“We are proud to share our scientific research demonstrating Rutherrin®'s unique characteristics in the destruction of cancer… positioning it as a potential breakthrough in the management of aggressive cancers.” – Roger DuMoulin‑White, B.Sc., P.Eng., Pro.Dir., President & CEO